A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients With Unresectable Stage III and IV Melanoma

Trial Profile

A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients With Unresectable Stage III and IV Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Feb 2018

At a glance

  • Drugs Denosumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CHARLI
  • Most Recent Events

    • 14 Dec 2017 Planned End Date changed from 1 Dec 2022 to 1 Jun 2023.
    • 14 Dec 2017 Planned primary completion date changed from 1 Dec 2019 to 1 Jun 2021.
    • 14 Dec 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top